PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma

This is a multisite, phase I/II clinical trial in children and young adults with newly-diagnosed high-grade glioma (HGG), diffuse midline glioma (DMG) and recurrent HGG/DMG, Medulloblastoma (MB), or ependymoma (EPN) to determine the safety, immunogenicity, and efficacy of a CMV-directed peptide vaccine plus checkpoint blockade.

Trial Details

NCT ID
NCT06639607
Phase
PHASE1 / PHASE2
Sponsor
Washington University School of Medicine
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • PEP-CMV vaccine
  • Tetanus booster
  • Nivolumab
  • Temozolomide
Locations (sample)
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Durham, North Carolina, United States|35.99403,-78.89862
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Patients must be ≥4 and ≤25 years of age (inclusive) at the time of study enrollment
  • Metastatic Disease: Patients with M+ disease are eligible.
  • Adequate bone marrow function defined as:
  • ANC (Absolute neutrophil count) ≥ 1000/µl.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →